Quarterly report pursuant to Section 13 or 15(d)

Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables)

v3.21.1
Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables)
9 Months Ended
Mar. 31, 2021
Notes Tables  
Schedule of Stockholders Equity [Table Text Block]
   

Bio-Techne Shareholders

                 
                                   

Accumulated

                 
                   

Additional

           

Other

                 
   

Common Stock

   

Paid-in

   

Retained

   

Comprehensive

   

Noncontrolling

         
   

Shares

   

Amount

   

Capital

   

Earnings

   

Income(Loss)

   

Interest

   

Total

 

Balances at June 30, 2020

    38,453     $ 385     $ 420,536     $ 1,057,470     $ (97,199

)

  $ -     $ 1,381,192  

Cumulative effect adjustments due to adoption of new accounting standards

                            (276

)

                    (276

)

Net earnings

                            33,395                       33,395  

Other comprehensive income

                                    14,057               14,057  

Common stock issued for exercise of options

    117       1       13,727                               13,728  

Common stock issued for restricted stock awards

    25       0       (0

)

    (4,890

)

                    (4,890

)

Cash dividends

                            (12,336

)

                    (12,336

)

Stock-based compensation expense

                    12,667                               12,667  

Common stock issued to employee stock purchase plan

    6       0       1,463                               1,463  

Employee stock purchase plan expense

                    286                               286  

Balances at September 30, 2020

    38,601     $ 386     $ 448,679     $ 1,073,362     $ (83,142

)

  $ -     $ 1,439,285  

Non-controlling interest in Eminence

                                            8,985       8,985  

Net earnings

                            46,274               (130

)

    46,144  

Other comprehensive income

                                    18,904       83       18,987  

Common stock issued for exercise of options

    161       2       16,748       (2,482

)

                    14,268  

Common stock issued for restricted stock awards

    3       0       (0

)

    0                       0  

Cash dividends

                            (12,392

)

                    (12,392

)

Stock-based compensation expense

                    15,471                               15,471  

Employee stock purchase plan expense

                    106                               106  

Balances at December 31, 2020

    38,765     $ 388     $ 481,004     $ 1,104,762     $ (64,238

)

  $ 8,938     $ 1,530,854  
Net earnings                             45,782               (380 )     45,402  
Other comprehensive income                                     215       (69 )     146  
Share repurchases     (120 )     (1 )             (43,177 )                     (43,178 )
Common stock issued for exercise of options     195       2       21,324       (4,332 )                     16,994  
Common stock issued for restricted stock awards     10       0       (0 )     (1,801 )                     (1,801 )
Cash dividends                             (12,446 )                     (12,446 )
Stock-based compensation expense                     10,232                               10,232  
       Common Stock issued to employee stock purchase plan     4       0       1,328                               1,328  

Employee stock purchase plan expense

                    411                               411  
Balances at March 31, 2021     38,854     $ 389     $ 514,299     $ 1,088,788     $ (64,023 )   $ 8,489     $ 1,547,942  
                                   

Accumulated

         
                   

Additional

           

Other

         
   

Common Stock

   

Paid-in

   

Retained

   

Comprehensive

         
   

Shares

   

Amount

   

Capital

   

Earnings

   

Income(Loss)

   

Total

 

Balances at June 30, 2019

    37,934     $ 379     $ 316,797     $ 931,934     $ (83,521

)

  $ 1,165,589  

Cumulative effect adjustments due to adoption of new accounting standards and other

                            (879

)

            (879

)

Net earnings

                            14,398               14,398  

Other comprehensive loss

                                    (8,106

)

    (8,106

)

Common stock issued for exercise of options

    94       1       7,854                       7,855  

Common stock issued for restricted stock awards

    50       0       (0

)

    (1,926

)

          (1,926

)

Cash dividends

                            (12,169

)

          (12,169

)

Stock-based compensation expense

                    8,267                       8,267  

Common stock issued to employee stock purchase plan

    6       0       1,096                       1,096  

Employee stock purchase plan expense

                    99                       99  

Balances at September 30, 2019

    38,084     $ 381     $ 334,112     $ 931,358     $ (91,627

)

  $ 1,174,224  

Net earnings

                            119,622               119,622  

Other comprehensive loss

                                    13,275       13,275  

Common stock issued for exercise of options

    195       2       18,293                       18,295  

Common stock issued for restricted stock awards

    4       0       (0

)

                    0  

Cash dividends

                            (12,197

)

            (12,197

)

Stock-based compensation expense

                    10,017                       10,017  

Common stock issued to employee stock purchase plan

                                               

Employee stock purchase plan expense

                    112                       112  

Balances at December 31, 2019

    38,283     $ 383     $ 362,534     $ 1,038,783     $ (78,352

)

  $ 1,323,348  
Net earnings                             36,432               36,432  
Other comprehensive income (loss)                                     (25,105 )     (25,105 )
Share Repurchases     (279 )     (3)       0       (50,109 )             (50,112 )
Common stock issued for exercise of options     100       1       10,026                       10,027  
Common stock issued for restricted stock awards     1       0       (0 )     (114 )             (114 )
Cash dividends                             (12,279 )             (12,279 )
Stock-based compensation expense                     7,745                       7,745  
Common stock issued to employee stock purchase plan     8       0       1,216                       1,216  
Employee stock purchase plan expense                     110                       110  
Balances at March 31, 2020     38,112     $ 381     $ 381,632     $ 1,012,713     $ (103,458 )   $ 1,291,268  
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]
   

Unrealized

Gains

(Losses) on

Derivative

Instruments

   

Foreign

Currency

Translation

Adjustments

   

Total

 

Balance as of June 30, 2020 attributable to Bio-Techne

  $ (13,253

)

  $ (83,946

)

  $ (97,199

)

Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne

    (13 )     27,686       27,673  

Reclassification from loss on derivatives to earnings, net of taxes, attributable to Bio-Techne(1)

    5,503       -       5,503  

Balance as of March 31, 2021 attributable to Bio-Techne(3)

  $ (7,763

)

  $ (56,260

)

  $ (64,023

)

   

Unrealized

Gains

(Losses) on

Derivative

Instruments

   

Foreign

Currency

Translation

Adjustments

   

Total

 

Balance as of June 30, 2019 attributable to Bio-Techne

  $ (9,537

)

  $ (73,983

)

  $ (83,521

)

Other comprehensive income (loss), net of tax before reclassifications, attributable to Bio-Techne

    (6,413 )     (15,138 )     (21,551 )

Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(2)

    1,614       -       1,614  

Balance as of March 31, 2020 attributable to Bio-Techne(3)

  $ (14,336

)

  $ (89,121

)

  $ (103,458

)